Impact BioMedical Inc. (IBO)
IBO trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1834105/000149315226009711/0001493152-26-009711-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | IBO on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Not reported by the screener |
| IPO year | 2024 |
| SEC CIK | 0001834105 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $32K |
| Net income | -$11.8M |
| Operating income | -$4.3M |
| Net margin | -36993.8% |
| Operating margin | -13381.3% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $3K |
| Total assets | $17.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1325.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt about the Company's ability to continue as a going concern within one year of the date that the financial statements are issued." | 10-Q 2026-11-09 |
| Cash and burn | $21K cash; operating cash flow $29K a quarter. | Report 2026-09-30 |
| Shares outstanding | 8,640,000 (2026-11-05); 104,621,231 a year earlier; 10,000,000 three years earlier. 1y figure adjusted for split (1-for-12.658 overall); 3y figure adjusted for split (1-for-12.658 overall). | Cover page 2026-11-05 |
| Reverse splits, 3 years | 1; latest 1-for-12.658 on 2026-09-23 | Source 2026-09-23 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Grassi & Co., CPAs, P.C., Jericho, New York, United States | PCAOB Form AP 2026-03-16 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $59K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $21K | -$645K | $11K | $21K | No debt tags | $38K | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $3K | -$699K | $470K | $10K | No debt tags | $35K | 10-Q 2026-08-07 |
| Q1 2026 2026-03-31 | $7K | -$2.3M | -$464K | $20K | No debt tags | $39K | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $7K | $5.2M | $99K | $3K | No debt tags | $32K | 10-K 2026-03-11 |
| Q3 2025 2025-09-30 | $18K | -$1.5M | -$613K | $12K | $22.9M | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $7K | -$14.3M | -$694K | $624K | $22.4M | Needs four quarters | 10-Q 2026-08-07 |
| Q1 2025 2025-03-31 | Not filed | -$1.3M | -$682K | $1.3M | $9.1M | Needs four quarters | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | Not filed | -$27.1M | -$986K | $2.0M | $21.0M | Needs four quarters | 10-K 2026-03-11 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2024-09-17 |
| Latest annual report | 10-K | 2026-03-11 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy | DEFM14A | 2026-10-27 |
Source: SEC EDGAR submissions feed, 156 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +25.4% |
| 1 month | +29.1% |
| 3 months | -7.7% |
| Year to date | -19.6% |
| 1 year | -20.4% |
| From 52-week high | -47.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ELTX | Elicio Therapeutics Inc. | $1.48 | -1.33% | $41.9M |
| PLRX | Pliant Therapeutics Inc. | $0.6932 | -0.55% | $43.0M |
| GANX | Gain Therapeutics Inc. | $0.9402 | -9.60% | $41.9M |
| DWTX | Dogwood Therapeutics Inc. | $1.06 | -8.62% | $40.5M |
| CNTB | Connect Biopharma Holdings Limited | $0.6430 | -5.05% | $40.5M |
| ALDX | Aldeyra Therapeutics Inc. | $0.6696 | +4.01% | $40.4M |
| ONCY | Oncolytics Biotech Inc. | $0.3399 | -8.14% | $44.6M |
| HYFT | MindWalk Holdings Corp. | $0.9378 | -8.95% | $44.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier